Merck entered a $510 million collaboration with Protillion Therapeutics to leverage AI for drug discovery. Following this, the company announced that its Phase 3 ATLAS-UC study of tulisokibart successfully met its primary and key secondary endpoints. The anti-TL1A antibody demonstrated positive results in late-stage trials for patients suffering from ulcerative colitis.
Merck's anti-TL1A antibody met its primary goals in a late-stage study, supporting the company's strategy to diversify revenue ahead of key patent expirations.
Read the full storyMerck announced that its Phase 3 ATLAS-UC study met primary and secondary endpoints, marking a milestone in monoclonal antibody treatments for gastrointestinal diseases.
The pharmaceutical giant partners with Protillion to leverage AI-driven protein engineering, aiming to accelerate its therapeutic pipeline through a $510 million collaboration.